Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject must have undergone a single clinical attack.~2. The subject must have a unifocal clinical presentation.~3. The subject should be enrolled within the period of 90 days after onset of a single unifocal clinical attack (index attack).~4. There must be 2 or more cerebral lesions highly suspicious of multiple sclerosis (MS) on the screening Magnetic Resonance Imaging (MRI), measuring 6mm or more in diameter.~5. Subjects must be between the ages of 18 and 45 years inclusive.~6. Subjects must not have taken corticosteroids within the 30 days prior to the MRI at the baseline visit.~7. Subjects may be male or female. Women of child-bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or intrauterine device with spermicide).~8. The subjects must be willing and able to give written informed consent, prior to entering the study.~Exclusion Criteria:~1. Multifocal clinical presentation.~2. Diseases other than MS responsible for the clinical/MRI presentation. The following laboratory tests must be part of the subject's medical history for differential diagnosis of clinically isolated syndrome (CIS): erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), complement (C3, C4) and anticardiolipin IgG - IgM. In the event that the results of these tests are inconclusive, the following additional tests may be requested by the Eligibility Evaluation Committee: syphilis screening, vitamin B12 and folic acid. In the case of spinal cord CIS presentation, a spinal cord MRI is required for confirmation of diagnosis in the medical history of the subject.~3. Use of experimental or investigational drugs, including IV immunoglobulin, and/or participation in an investigational drug study within 6 months prior to study entry.~4. Use of interferon agents within 6 months prior to the screening visit.~5. Chronic corticosteroid treatment (more than 30 consecutive days) in the 6 months prior to study entry.~6. Pregnancy or breast feeding.~7. Subjects who experience a relapse between the screening (month -1) and baseline (month 0) visits.~8. Life-threatening or other clinically significant disease.~9. A medical or psychiatric condition that affects the subject's ability to give informed consent, or to complete the study, or if the subject is considered by the treating neurologist/physician to be, for any other reason, an unsuitable candidate for this study.~10. A known history of sensitivity to mannitol.~11. A known history of sensitivity to gadolinium.~12. Inability to successfully undergo MRI scanning.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Glatiramer acetate (Type: EXPERIMENTAL): Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
- Placebo (DB) to GA (OL) (Type: PLACEBO_COMPARATOR): Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete